Julie R Howle
Overview
Explore the profile of Julie R Howle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rowse B, Yu A, Faulkner H, Sandler G, Howle J, Chng S, et al.
ANZ J Surg
. 2023 Jun;
93(7-8):1970-1977.
PMID: 37303266
Purpose: This study aimed to determine the diagnostic accuracy of CT and MRI in the preoperative detection of bone involvement for non-melanoma skin cancers (NMSCs) located on the scalp. This...
2.
Varey A, Thompson J, Howle J, Lo S, Chng S, Carlino M
Eur J Cancer
. 2023 Apr;
186:166-171.
PMID: 37080117
The prognostic value of sentinel node biopsy (SNB) is well established and SNB was therefore adopted as a requirement for pathological staging of melanomas>1 mm thick in the American Joint...
3.
Hasmat S, Howle J, Carlino M, Sundaresan P, Veness M
ANZ J Surg
. 2022 Dec;
93(1-2):235-241.
PMID: 36567642
Background: Cutaneous squamous cell carcinoma (CSCC) is the second most common malignancy in the Caucasian population. A minority of cases are inoperable at presentation, recur or develop metastatic disease with...
4.
Scolyer R, Atkinson V, Gyorki D, Lambie D, OToole S, Saw R, et al.
Pathology
. 2021 Dec;
54(1):6-19.
PMID: 34937664
Targeted therapy (BRAF inhibitor plus MEK inhibitor) is now among the possible treatment options for patients with BRAF mutation-positive stage III or stage IV melanoma. This makes prompt BRAF mutation...
5.
Howle J, Varey A, Carlino M
ANZ J Surg
. 2021 Dec;
91(12):2557-2558.
PMID: 34913561
No abstract available.
6.
Truong K, Goldinger S, Chou S, Howle J, Veness M, Fernandez-Penas P, et al.
Australas J Dermatol
. 2021 Dec;
63(1):e6-e12.
PMID: 34873684
Background: Merkel cell carcinoma (MCC) is a rare primary cutaneous neuroendocrine tumour. While dermally invasive MCC is known to have a five-year survival of only 30-40%, the prognosis and management...
7.
Li A, Vakharia K, Lo S, Varey A, Carlino M, Saw R, et al.
Ann Surg Oncol
. 2021 Aug;
28(11):6109-6123.
PMID: 34347220
Background: Metastasectomy for selected patients with melanoma was associated with improved survival in the era before effective systemic therapy. Emerging evidence shows that these benefits persist even in this era...
8.
Hasmat S, Howle J, Karikios D, Carlino M, Veness M
J Med Imaging Radiat Oncol
. 2021 May;
65(6):760-767.
PMID: 34053196
Introduction: Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with no survival benefit demonstrated using palliative cytotoxic chemotherapy in the setting of metastatic MCC. Recently, immune checkpoint inhibitors...
9.
Yang P, Veness M, Cooper E, Fox R, Smee R, Lehane C, et al.
ANZ J Surg
. 2021 Jan;
91(5):878-884.
PMID: 33506995
Background: Metastatic cutaneous squamous cell carcinoma to the axilla is uncommon, with limited data to guide management. We sought to assess the outcomes of patients with this condition after surgery...
10.
Diefenbach R, Lee J, Menzies A, Carlino M, Long G, Saw R, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32785074
Detection of melanoma-associated mutations using circulating tumor DNA (ctDNA) from plasma is a potential alternative to using genomic DNA from invasive tissue biopsies. In this study, we developed a custom...